Skip to content
Screener

Haemonetics HAE Apheresis — Restructuring related costs

Other segment segments

Corporate
-$40K—
MedSurg
$0—

Similar metrics at other companies

Novanta logo
NOVTUnallocated Costs — Restructuring And Related Cost Incurred Cost
$856.75K+312%
Regal Rexnord logo
RRXRestructuring And Related Cost Expected Cost1
$13.6M+5.4%
MBC
MBCRestructuring And Related Cost Expected Cost1
$8.1M—
Xerox Holdings Corporation logo
XRXRestructuring And Related Cost Expected Cost1
$78M+21.9%
Bumble, Inc. logo
BMBLRestructuring And Related Cost Expected Cost1
$16M—
Matthews International logo
MATWRestructuring And Related Cost Expected Cost1
$42M—

Other financials

Income statement

See full
Revenue$339.4M+5.6%
Gross profit$202.8M+5.5%
Operating income$57.5M+6.7%
Net income$33.0M-3.0%
EPS (diluted)$0.72+2.9%

Balance sheet

See full
Cash & equivalents$223.4M-23.7%
Total debt$1.2B-4.1%
Total equity$837.1M-5.1%
Total assets$2.4B-3.9%

Cash flow

See full
Operating cash flow$52.3M+201%
CapEx$7.9M+111%
Free cash flow$44.4M+226%

Valuation

See full
Market cap$3.87B+6.3%
Enterprise value$4.82B+5.4%
P/E25.7×-10.5×
P/S2.9×+0.2×

Profitability

See full
Gross margin59%+2.1pp
Operating margin19%+5.9pp
Net margin13.3%+3.8pp
FCF margin21.5%+7.5pp

Returns & leverage

See full
Return on equity19.3%+5.2pp
Debt / equity1.4×0.0×
Current ratio3.1×+1.4×

Where this comes from

Reported directly by Haemonetics in its filing.

Tagged under the XBRL concept hae:RestructuringRelatedCosts.

The source filing: Haemonetics’s 10-Q, filed August 6, 2026.

Filed
Aug 6, 2026, 6:09 AM EDT
Fiscal quarter
Q1 FY2027
Calendar quarter
Q2 2026
Accession
0000313143-26-000120
Line itemThree Months Ended / June 27, 2026Three Months Ended / June 28, 2025
Corporate(24)1,142
Total$2,298$1,266
Restructuring related costs
Apheresis—$9
MedSurg——
Corporate(40)49
Total$(40)$58
Total restructuring and restructuring related costs$2,258$1,324

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is Haemonetics's apheresis — restructuring related costs?
Haemonetics (HAE) reported apheresis — restructuring related costs of $0 in Q2 2026.
What does apheresis — restructuring related costs mean?
These are non-recurring expenses associated with organizational changes, facility consolidations, or workforce reductions within the Apheresis segment. Tracking these costs is essential for distinguishing between core operational performance and one-time charges related to strategic realignments. High levels of these costs may indicate significant internal transformation efforts.

Ask your AI about Haemonetics's apheresis — restructuring related costs.

Connect your AI assistant and compare segments, right in your chat.

Connect your AI
Harbor at dusk
Claude